Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07280702 · ClinicalTrials.gov registry record · Phase 4
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 128
- Enrollment target
NCT07280702: Clinical Trial Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
NCT07280702 is a Phase 4 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 128 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07280702, a Phase 4 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 128 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.
Primary Outcome
Proportion of patients achieving a novel composite endpoint of BSA \</= 1 AND SJC \</= 1) OR (BSA \</= 1 AND TJC \</= 1) at 24 weeks
Interventions
- DRUG Placebo
- DRUG Deucravacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2027-12-15 |
| Phase | Phase 4 |
What is known before NCT07280702 opens enrollment
NCT07280702 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07280702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07280702 about?
NCT07280702 is a clinical study titled "Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease". The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of...
What is the current status of trial NCT07280702?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2026-04-15. Estimated completion is 2027-12-15.
What interventions are being tested in trial NCT07280702?
The interventions under investigation include: Placebo (DRUG), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT07280702?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07280702's enrollment target sits among peer trials
128 634th of 2000 higher than 1,362 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI